<?xml version='1.0' encoding='utf-8'?>
<document id="24452746"><sentence text="Effect of steady-state atorvastatin on the pharmacokinetics of a single dose of colchicine in healthy adults under fasted conditions."><entity charOffset="23-35" id="DDI-PubMed.24452746.s1.e0" text="atorvastatin" /><entity charOffset="80-90" id="DDI-PubMed.24452746.s1.e1" text="colchicine" /><pair ddi="false" e1="DDI-PubMed.24452746.s1.e0" e2="DDI-PubMed.24452746.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24452746.s1.e0" e2="DDI-PubMed.24452746.s1.e1" /></sentence><sentence text="Colchicine is commonly prescribed for gout"><entity charOffset="0-10" id="DDI-PubMed.24452746.s2.e0" text="Colchicine" /></sentence><sentence text=" While minimally metabolized by the cytochrome P450 (CYP) 3A4 isoenzyme, colchicine is a substrate for P-glycoprotein (P-gp)"><entity charOffset="73-83" id="DDI-PubMed.24452746.s3.e0" text="colchicine" /></sentence><sentence text=" Atorvastatin is metabolized primarily by CYP3A4 and is a P-gp inhibitor"><entity charOffset="1-13" id="DDI-PubMed.24452746.s4.e0" text="Atorvastatin" /></sentence><sentence text=" Patients with gout often have dyslipidemia; therefore, the potential for co-administration of atorvastatin and colchicine exists"><entity charOffset="95-107" id="DDI-PubMed.24452746.s5.e0" text="atorvastatin" /><entity charOffset="112-122" id="DDI-PubMed.24452746.s5.e1" text="colchicine" /><pair ddi="false" e1="DDI-PubMed.24452746.s5.e0" e2="DDI-PubMed.24452746.s5.e0" /><pair ddi="false" e1="DDI-PubMed.24452746.s5.e0" e2="DDI-PubMed.24452746.s5.e1" /></sentence><sentence text=" The objective of this study was to determine the effect of oral atorvastatin on the pharmacokinetics of a single, oral dose of colchicine"><entity charOffset="65-77" id="DDI-PubMed.24452746.s6.e0" text="atorvastatin" /><entity charOffset="128-138" id="DDI-PubMed.24452746.s6.e1" text="colchicine" /><pair ddi="false" e1="DDI-PubMed.24452746.s6.e0" e2="DDI-PubMed.24452746.s6.e0" /><pair ddi="false" e1="DDI-PubMed.24452746.s6.e0" e2="DDI-PubMed.24452746.s6.e1" /></sentence><sentence text="" /><sentence text="Twenty-four healthy adult subjects were enrolled in this single-center, open-label, non-randomized, one-sequence, two-period drug-drug interaction study" /><sentence text=" On day 1, subjects received a single oral dose of colchicine 0"><entity charOffset="51-61" id="DDI-PubMed.24452746.s9.e0" text="colchicine" /></sentence><sentence text="6 mg" /><sentence text=" After a 14-day washout, subjects received atorvastatin 40 mg once daily for 14 days followed by a single dose of colchicine 0"><entity charOffset="43-55" id="DDI-PubMed.24452746.s11.e0" text="atorvastatin" /><entity charOffset="114-124" id="DDI-PubMed.24452746.s11.e1" text="colchicine" /><pair ddi="false" e1="DDI-PubMed.24452746.s11.e0" e2="DDI-PubMed.24452746.s11.e0" /><pair ddi="false" e1="DDI-PubMed.24452746.s11.e0" e2="DDI-PubMed.24452746.s11.e1" /></sentence><sentence text="6 mg co-administered with atorvastatin 40 mg on day 28"><entity charOffset="26-38" id="DDI-PubMed.24452746.s12.e0" text="atorvastatin" /></sentence><sentence text=" Main outcome measures were colchicine maximum plasma concentration (C max), area under the plasma concentration-time curve (AUC) from time zero to the last measurable concentration (AUC last), and AUC from time zero to infinity (AUC∞), which were compared with and without concurrent atorvastatin"><entity charOffset="28-38" id="DDI-PubMed.24452746.s13.e0" text="colchicine" /><entity charOffset="285-297" id="DDI-PubMed.24452746.s13.e1" text="atorvastatin" /><pair ddi="false" e1="DDI-PubMed.24452746.s13.e0" e2="DDI-PubMed.24452746.s13.e0" /><pair ddi="false" e1="DDI-PubMed.24452746.s13.e0" e2="DDI-PubMed.24452746.s13.e1" /></sentence><sentence text="" /><sentence text="Colchicine AUC last, AUC∞, and C max increased by 27, 24, and 31 %, respectively, when co-administered with atorvastatin"><entity charOffset="0-10" id="DDI-PubMed.24452746.s15.e0" text="Colchicine" /><entity charOffset="108-120" id="DDI-PubMed.24452746.s15.e1" text="atorvastatin" /><pair ddi="false" e1="DDI-PubMed.24452746.s15.e0" e2="DDI-PubMed.24452746.s15.e0" /><pair ddi="false" e1="DDI-PubMed.24452746.s15.e0" e2="DDI-PubMed.24452746.s15.e1" /></sentence><sentence text=" Corresponding 90 % confidence intervals around the ratios were outside the established no-effect 80-125 % interval" /><sentence text="" /><sentence text="Increased colchicine exposure was observed after a single dose of colchicine was administered with steady-state atorvastatin"><entity charOffset="10-20" id="DDI-PubMed.24452746.s18.e0" text="colchicine" /><entity charOffset="66-76" id="DDI-PubMed.24452746.s18.e1" text="colchicine" /><entity charOffset="112-124" id="DDI-PubMed.24452746.s18.e2" text="atorvastatin" /><pair ddi="false" e1="DDI-PubMed.24452746.s18.e0" e2="DDI-PubMed.24452746.s18.e0" /><pair ddi="false" e1="DDI-PubMed.24452746.s18.e0" e2="DDI-PubMed.24452746.s18.e1" /><pair ddi="false" e1="DDI-PubMed.24452746.s18.e0" e2="DDI-PubMed.24452746.s18.e2" /><pair ddi="false" e1="DDI-PubMed.24452746.s18.e1" e2="DDI-PubMed.24452746.s18.e1" /><pair ddi="false" e1="DDI-PubMed.24452746.s18.e1" e2="DDI-PubMed.24452746.s18.e2" /></sentence><sentence text=" Additional studies with multiple dosing of both drugs are needed to further determine the clinical implications of these results" /><sentence text="" /></document>